The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment
about
Phytoestrogen biological actions on Mammalian reproductive system and cancer growthA semi-supervised method for drug-target interaction prediction with consistency in networksHistone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor proteinNovel oestrogen receptor β-selective ligand reduces obesity and depressive-like behaviour in ovariectomized mice.Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.Aberrant expression of regulators of cell-fate found in eutopic endometrium is found in matched ectopic endometrium among women and in a baboon model of endometriosis.Selective ligands of estrogen receptor β discovered using pharmacophore mapping and structure-based virtual screening.Structural and Functional Diversity of Estrogen Receptor Ligands.The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomesIsoflavones and Prostate Cancer: A Review of Some Critical Issues.Differential regulation of oestrogen receptor β isoforms by 5' untranslated regions in cancerComprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificityErb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway.Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer.Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.Sorghum phenolics demonstrate estrogenic action and induce apoptosis in nonmalignant colonocytes.SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo.Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.Expression of prostate stem cell antigen is downregulated during flavonoid-induced cytotoxicity in prostate cancer cells.Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC).Tectorigenin and its inhibitory effects on tumor growth in systemic malignancies.Aberrant expression of signaling proteins in essential thrombocythemia.Comparative Analysis of Proteins with Stimulating Activity on Ovarian Estradiol Biosynthesis from Four Different Dioscorea Species in vitro Using Both Phenotypic and Target-based Approaches: Implication for Treating Menopause.An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer.E2/ERβ Inhibits PPARα to Regulate Cell-Proliferation and Enhance Apoptosis in Hep3B-Hepatocellular Carcinoma.Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer.Levetiracetam exhibits protective properties on rat Schwann cells in vitro.
P2860
Q24633150-BCB858A9-F920-4E67-A1AA-06D8F691B4F8Q28487735-D483CE73-B793-4C99-90AF-03FDAB8AF9FDQ33796184-BD6DB154-C4F8-4A04-B797-E8EB7B613618Q33875276-4D98102E-7C8C-4C4B-8F3B-A37EE4AE30D2Q33944679-77FA29C6-92F7-4074-B554-97C442F078ACQ34202542-CCED150D-3607-4E1D-BBF0-732406B021EBQ34295026-FB32D92E-7A8C-40C6-97E7-E55908806892Q35599990-480ABC51-8EC8-43E1-9F79-22CA91C1CF87Q35609249-4C6E956C-FC1F-4DBD-BAF0-529B7E169922Q36705608-B82F631D-2698-45EE-AA40-0E6F4B1116F8Q37294996-BBA777D2-FD76-43DC-B15B-B1D55E40F002Q37582438-175FCF0C-6AA4-45F7-890E-07C7D5D322CEQ37624094-6051A54A-6CF8-4C3A-8C23-673DFBD34642Q38708804-1D1D856A-3694-4A41-BC5E-37B331B1E0B0Q39123647-D25F4C4D-BA2B-46A1-9854-A2186DFD0EFDQ39204978-83D21F7D-E50C-4121-9483-A3BEB413F740Q39389632-BB32318B-FDFF-4CB7-964E-F12E919651B0Q39628302-41748D15-F1C7-4DA1-829A-36C71750CF52Q39652928-0543A81C-8A2D-44F9-9B78-2C109E3BE5CAQ41116482-9F0A887F-B035-4303-A2FA-B8BB47E42D98Q42927475-C1F20B07-A29D-4166-965F-71602EF2E592Q44179584-94BE0797-6A6A-4DAF-AD0D-F29F482EA618Q44482944-4A0F3A25-92AD-4DE2-8743-5CC14B5B999AQ46555307-FA467ED3-8A1D-463A-95A2-8CAAAF0F79D7Q47601018-070FD84C-DDEF-4D26-B2A2-23A38AB1E15BQ48038751-60C461AD-FA34-45A4-A773-7D7876FF27F1Q49080367-E3388009-2151-4E24-B19E-B8E0CF218350Q52571247-6B11C273-9B7F-45C5-AF5B-5AFCD3D67A45Q54343673-9D20041F-791C-4FF4-B3EE-C09A48B314BC
P2860
The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The relevance of estrogen rece ...... s in prostate cancer treatment
@ast
The relevance of estrogen rece ...... s in prostate cancer treatment
@en
The relevance of estrogen rece ...... s in prostate cancer treatment
@nl
type
label
The relevance of estrogen rece ...... s in prostate cancer treatment
@ast
The relevance of estrogen rece ...... s in prostate cancer treatment
@en
The relevance of estrogen rece ...... s in prostate cancer treatment
@nl
prefLabel
The relevance of estrogen rece ...... s in prostate cancer treatment
@ast
The relevance of estrogen rece ...... s in prostate cancer treatment
@en
The relevance of estrogen rece ...... s in prostate cancer treatment
@nl
P2093
P1476
The relevance of estrogen rece ...... s in prostate cancer treatment
@en
P2093
Arne Strauss
Mark Stettner
Paul Thelen
Peter Burfeind
Rolf-Hermann Ringert
Silke Kaulfuss
Stefan Schweyer
P304
P356
10.1158/1535-7163.MCT-07-0197
P407
P577
2007-10-01T00:00:00Z